Lisa M Bebell1,2,3, Mark J Siedner1,2,3, Joseph Ngonzi4, Mylinh H Le3, Julian Adong4, Adeline A Boatin2,5, Ingrid V Bassett1,3, Drucilla J Roberts6. 1. Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA. 2. Center for Global Health, Massachusetts General Hospital, Boston, MA. 3. Medical Practice Evaluation Center of Massachusetts General Hospital, Boston, MA. 4. Mbarara University of Science and Technology, Mbarara, Uganda; and. 5. Departments of Obstetrics and Gynecology; and. 6. Pathology, Massachusetts General Hospital, Boston, MA.
Abstract
BACKGROUND: HIV-exposed, uninfected (HEU) children have poorer early-life outcomes than HIV-unexposed children. The determinants of adverse health outcomes among HEU children are poorly understood but may result from chronic placental inflammation (CPI). SETTING AND METHODS: We enrolled 176 pregnant women living with HIV (WLWH) taking antiretroviral therapy in southwestern Uganda and 176 HIV-uninfected women to compare CPI prevalence by maternal HIV serostatus. Placentas were evaluated histologically by an expert pathologist for presence of CPI, defined as chronic chorioamnionitis, plasma cell deciduitis, villitis of unknown etiology, or chronic histiocytic intervillositis. Placentas with CPI were additionally immunostained with CD3 (T cell), CD20 (B cell), and CD68 (macrophage) markers to characterize inflammatory cell profiles. RESULTS: WLWH and HIV-uninfected women had similar age, parity, and gestational age. Among WLWH, the mean CD4 count was 480 cells/µL, and 74% had an undetectable HIV viral load. We detected CPI in 16 (9%) placentas from WLWH and 24 (14%) from HIV-uninfected women (P = 0.18). Among WLWH, CPI was not associated with the CD4 count or HIV viral load. Villitis of unknown etiology was twice as common among HIV-uninfected women than WLWH (10 vs. 5%, P = 0.04). Among placentas with CPI, more villous inflammatory cells stained for CD3 or CD68 among HIV-uninfected women than WLWH (79% vs. 46%, P = 0.07). CONCLUSIONS: CPI prevalence did not differ by HIV serostatus. T-cell (CD3) and macrophage (CD68) markers were more prevalent in placental inflammatory cells from HIV-uninfected women. Our results do not support CPI as a leading mechanism for poor outcomes among HEU children in the antiretroviral therapy era.
BACKGROUND: HIV-exposed, uninfected (HEU) children have poorer early-life outcomes than HIV-unexposed children. The determinants of adverse health outcomes among HEU children are poorly understood but may result from chronic placental inflammation (CPI). SETTING AND METHODS: We enrolled 176 pregnant women living with HIV (WLWH) taking antiretroviral therapy in southwestern Uganda and 176 HIV-uninfected women to compare CPI prevalence by maternal HIV serostatus. Placentas were evaluated histologically by an expert pathologist for presence of CPI, defined as chronic chorioamnionitis, plasma cell deciduitis, villitis of unknown etiology, or chronic histiocytic intervillositis. Placentas with CPI were additionally immunostained with CD3 (T cell), CD20 (B cell), and CD68 (macrophage) markers to characterize inflammatory cell profiles. RESULTS: WLWH and HIV-uninfected women had similar age, parity, and gestational age. Among WLWH, the mean CD4 count was 480 cells/µL, and 74% had an undetectable HIV viral load. We detected CPI in 16 (9%) placentas from WLWH and 24 (14%) from HIV-uninfected women (P = 0.18). Among WLWH, CPI was not associated with the CD4 count or HIV viral load. Villitis of unknown etiology was twice as common among HIV-uninfected women than WLWH (10 vs. 5%, P = 0.04). Among placentas with CPI, more villous inflammatory cells stained for CD3 or CD68 among HIV-uninfected women than WLWH (79% vs. 46%, P = 0.07). CONCLUSIONS: CPI prevalence did not differ by HIV serostatus. T-cell (CD3) and macrophage (CD68) markers were more prevalent in placental inflammatory cells from HIV-uninfected women. Our results do not support CPI as a leading mechanism for poor outcomes among HEU children in the antiretroviral therapy era.
Authors: F Wabwire-Mangen; R H Gray; F A Mmiro; C Ndugwa; C Abramowsky; H Wabinga; C Whalen; C Li; A J Saah Journal: J Acquir Immune Defic Syndr Date: 1999-12-01 Impact factor: 3.731
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: D A Schwartz; S Sungkarat; N Shaffer; J Laosakkitiboran; W Supapol; P Charoenpanich; T Chuangsuwanich; T D Mastro Journal: J Infect Dis Date: 2000-11-08 Impact factor: 5.226
Authors: Anine Vermaak; Gerhard B Theron; Pawel T Schubert; Martin Kidd; Ursula Rabie; Benedict M Adjiba; Colleen A Wright Journal: Int J Gynaecol Obstet Date: 2012-09-08 Impact factor: 3.561
Authors: Judith K Stephens; Eric Kyei-Baafour; Emmanuel K Dickson; Jones K Ofori; Michael F Ofori; Mark L Wilson; Isabella A Quakyi; Bartholomew D Akanmori Journal: Malar J Date: 2017-05-26 Impact factor: 2.979
Authors: Sepideh Dolatshahi; Audrey L Butler; Mark J Siedner; Joseph Ngonzi; Andrea G Edlow; Julian Adong; Madeleine F Jennewein; Caroline Atyeo; Ingrid V Bassett; Drucilla J Roberts; Douglas A Lauffenburger; Galit Alter; Lisa M Bebell Journal: Clin Infect Dis Date: 2022-10-12 Impact factor: 20.999
Authors: Lisa M Bebell; Kalynn Parks; Mylinh H Le; Joseph Ngonzi; Julian Adong; Adeline A Boatin; Ingrid V Bassett; Mark J Siedner; Alison D Gernand; Drucilla J Roberts Journal: J Infect Dis Date: 2021-12-08 Impact factor: 5.226
Authors: Lisa M Bebell; Joseph Ngonzi; Frederick A Meier; Chrystalle Katte Carreon; Abraham Birungi; Vanessa B Kerry; Raymond Atwine; Drucilla J Roberts Journal: Front Med (Lausanne) Date: 2022-07-08